Persistent Asset Partners Ltd bought a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 41,404 shares of the company's stock, valued at approximately $260,000.
Several other institutional investors have also recently made changes to their positions in the stock. Point72 Asset Management L.P. bought a new stake in Trevi Therapeutics during the 4th quarter valued at approximately $17,099,000. Frazier Life Sciences Management L.P. raised its stake in Trevi Therapeutics by 44.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock valued at $43,939,000 after purchasing an additional 3,283,684 shares during the period. Woodline Partners LP increased its stake in Trevi Therapeutics by 429.9% in the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company's stock worth $13,236,000 after acquiring an additional 2,606,370 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Trevi Therapeutics in the 4th quarter worth approximately $10,300,000. Finally, Acorn Capital Advisors LLC bought a new stake in Trevi Therapeutics in the 4th quarter worth approximately $8,244,000. Institutional investors own 95.76% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have issued reports on the company. Wall Street Zen downgraded Trevi Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. D. Boral Capital restated a "buy" rating and set a $21.00 price objective on shares of Trevi Therapeutics in a report on Monday, June 2nd. Needham & Company LLC lowered their target price on Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday. Raymond James Financial reduced their target price on Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating on the stock in a research report on Friday. Finally, Cantor Fitzgerald started coverage on Trevi Therapeutics in a research report on Tuesday, July 1st. They set an "overweight" rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Trevi Therapeutics currently has an average rating of "Buy" and an average target price of $20.38.
View Our Latest Research Report on TRVI
Trevi Therapeutics Stock Performance
NASDAQ:TRVI opened at $7.32 on Tuesday. Trevi Therapeutics, Inc. has a one year low of $2.36 and a one year high of $8.11. The stock has a market cap of $858.56 million, a PE ratio of -17.43 and a beta of 0.58. The stock has a 50 day moving average price of $6.60 and a 200 day moving average price of $5.97.
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. As a group, analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.
About Trevi Therapeutics
(
Free Report)
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Trevi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.
While Trevi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access